Unspecified serine protease in the fibrinolysis pathway

The fibrinolysis pathway is a critical physiological process responsible for the enzymatic degradation of fibrin clots, ensuring the maintenance of blood flow and preventing permanent vascular occlusion (StatPearls). This pathway is primarily mediated by a group of serine proteases, including plasmin and its primary activators, tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) (NIH). Plasmin, the central enzyme of the system, is generated from the zymogen plasminogen and acts by cleaving fibrin into soluble degradation products (Wikipedia). These serine proteases are major therapeutic targets in cardiovascular medicine; plasminogen activators like alteplase are administered as thrombolytic therapy for acute ischemic stroke and myocardial infarction to rapidly dissolve life-threatening clots (PubChem). Conversely, inhibitors of this pathway, such as tranexamic acid, are utilized as antifibrinolytic agents to reduce blood loss in surgical and trauma settings (PubChem). Dysregulation of these enzymes can lead to either pathological thrombosis or severe bleeding disorders, depending on whether the system is underactive or overactive (NIH). Consequently, monitoring biomarkers like D-dimer and fibrin degradation products is essential for assessing the activity of these proteases in clinical practice (StatPearls). The balance between these proteases and their endogenous inhibitors, such as plasminogen activator inhibitor-1 (PAI-1), is vital for hemostatic stability (Wikipedia).

Other names

Fibrinolytic serine proteasePlasminogen activatorPlasmin-like proteaseThrombolytic target

Drugs targeting these proteases function either as thrombolytics by activating the zymogen plasminogen into active plasmin to dissolve fibrin clots, or as antifibrinolytics by inhibiting the activation or proteolytic activity of plasmin to prevent clot dissolution.